Imbalanced cholesterol metabolism in Alzheimer's disease

Clinica Chimica Acta

Volumn 456, Issue , 2016, Pages 107-114

  Xue Shan, Zhao ^a   juan, Peng ^a   Qi, Wu ^a   Zhong, Ren ^a   Li hong, Pan ^a   Zhi han, Tang ^a   Zhi Sheng, Jiang ^a   Gui xue, Wang ^b   Lu Shan, Liu ^a,b  

^a UNIVERSITY OF SOUTH CHINA   (China)

^b CHONGQING UNIVERSITY   (China)

Author keywords

Alzheimer's disease; ApoE; A ; Cholesterol; LRP1; PCSK9

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; CHOLESTEROL; KEXIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; OXYSTEROL; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; APOE GENE; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN METABOLISM; CHOLESTEROL METABOLISM; DISORDERS OF CHOLESTEROL METABOLISM; HUMAN; HYPERCHOLESTEROLEMIA; NERVE CELL; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN METABOLISM; REVIEW; RISK FACTOR; ANIMAL; COMPLICATION; GENETICS; METABOLISM;

ALZHEIMER DISEASE; ANIMALS; BLOOD-BRAIN BARRIER; CHOLESTEROL; HUMANS; HYPERCHOLESTEROLEMIA; RISK FACTORS;

EID: 84960444400     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2016.02.024     Document Type: Review

References (59)

1. Faller P., Hureau C. A bioinorganic view of Alzheimer's disease: when misplaced metal ions (re)direct the electrons to the wrong target. Chem. Weinheim Bergstr. Ger. 2012, 18:15910-15920.
2. Xiao Z., Wang J., Chen W., Wang P., Zeng H., Chen W. Association studies of several cholesterol-related genes (ABCA1, CETP and LIPC) with serum lipids and risk of Alzheimer's disease. Lipids Health Dis. 2012, 11:163.
3. Di Paolo G., Kim T.W. Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat. Rev. Neurosci. 2011, 12:284-296.
4. Zhang J., Liu Q. Cholesterol metabolism and homeostasis in the brain. Protein Cell 2015, 6:254-264.
5. Popp J., Meichsner S., Kolsch H., et al. Cerebral and extracerebral cholesterol metabolism and CSF markers of Alzheimer's disease. Biochem. Pharmacol. 2013, 86:37-42.
6. Kosari S., Badoer E., Nguyen J.C., Killcross A.S., Jenkins T.A. Effect of western and high fat diets on memory and cholinergic measures in the rat. Behav. Brain Res. 2012, 235:98-103.
7. Kivipelto M., Helkala E.L., Laakso M.P., et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann. Intern. Med. 2002, 137:149-155.
8. Solomon A., Kareholt I., Ngandu T., et al. Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology 2007, 68:751-756.
9. Helzner E.P., Luchsinger J.A., Scarmeas N., et al. Contribution of vascular risk factors to the progression in Alzheimer disease. Arch. Neurol. 2009, 66:343-348.
10. Pregelj P. Involvement of cholesterol in the pathogenesis of Alzheimer's disease: role of statins. Psychiatr. Danub. 2008, 20:162-167.
11. Shepardson N.E., Shankar G.M., Selkoe D.J. Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. Arch. Neurol. 2011, 68:1239-1244.
12. Longenberger J., Shah Z.A. Simvastatin and other HMG-CoA reductase inhibitors on brain cholesterol levels in Alzheimer's disease. Curr. Alzheimer Res. 2011, 8:434-442.
13. Lin F.C., Chuang Y.S., Hsieh H.M., et al. Early statin use and the progression of Alzheimer disease: a total population-based case-control study. Medicine 2015, 94.
14. Chan R.B., Oliveira T.G., Cortes E.P., et al. Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J. Biol. Chem. 2012, 287:2678-2688.
15. Mateos L., Akterin S., Gil-Bea F.J., et al. Activity-regulated cytoskeleton-associated protein in rodent brain is down-regulated by high fat diet in vivo and by 27-hydroxycholesterol in vitro. Brain Pathol. 2009, 19:69-80.
16. Ginsberg S.D., Hemby S.E., Lee V.M., Eberwine J.H., Trojanowski J.Q. Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons. Ann. Neurol. 2000, 48:77-87.
17. de Oliveira J., Hort M.A., Moreira E.L., et al. Positive correlation between elevated plasma cholesterol levels and cognitive impairments in LDL receptor knockout mice: relevance of cortico-cerebral mitochondrial dysfunction and oxidative stress. Neuroscience 2011, 197:99-106.
18. Ramirez C., Sierra S., Tercero I., et al. ApoB100/LDLR-/- hypercholesterolaemic mice as a model for mild cognitive impairment and neuronal damage. PLoS One 2011, 6.
19. Umeda T., Tomiyama T., Kitajima E., et al. Hypercholesterolemia accelerates intraneuronal accumulation of Abeta oligomers resulting in memory impairment in Alzheimer's disease model mice. Life Sci. 2012, 91:1169-1176.
20. Jiang X., Guo M., Su J., et al. Simvastatin blocks blood-brain barrier disruptions induced by elevated cholesterol both in vivo and in vitro. Int. J. Alzheimers Dis. 2012, 2012:109324.
21. Chen X., Gawryluk J.W., Wagener J.F., Ghribi O., Geiger J.D. Caffeine blocks disruption of blood brain barrier in a rabbit model of Alzheimer's disease. J. Neuroinflammation 2008, 5:12.
22. Dehouck B., Fenart L., Dehouck M.P., Pierce A., Torpier G., Cecchelli R. A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier. J. Cell Biol. 1997, 138:877-889.
23. Viola K.L., Klein W.L. Amyloid beta oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis. Acta Neuropathol. 2015, 129:183-206.
24. Beel A.J., Sakakura M., Barrett P.J., Sanders C.R. Direct binding of cholesterol to the amyloid precursor protein: an important interaction in lipid-Alzheimer's disease relationships?. Biochim. Biophys. Acta 1801, 2010:975-982.
25. Grimm M.O., Grimm H.S., Tomic I., Beyreuther K., Hartmann T., Bergmann C. Independent inhibition of Alzheimer disease beta- and gamma-secretase cleavage by lowered cholesterol levels. J. Biol. Chem. 2008, 283:11302-11311.
26. Huttunen H.J., Havas D., Peach C., et al. The acyl-coenzyme A: cholesterol acyltransferase inhibitor CI-1011 reverses diffuse brain amyloid pathology in aged amyloid precursor protein transgenic mice. J. Neuropathol. Exp. Neurol. 2010, 69:777-788.
27. Prasanthi J.R., Huls A., Thomasson S., Thompson A., Schommer E., Ghribi O. Differential effects of 24-hydroxycholesterol and 27-hydroxycholesterol on beta-amyloid precursor protein levels and processing in human neuroblastoma SH-SY5Y cells. Mol. Neurodegener. 2009, 4:1.
28. Hudry E., Van Dam D., Kulik W., et al. Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease. Mol. Ther. 2010, 18:44-53.
29. Heverin M., Bogdanovic N., Lutjohann D., et al. Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease. J. Lipid Res. 2004, 45:186-193.
30. Lathe R., Sapronova A., Kotelevtsev Y. Atherosclerosis and Alzheimer-diseases with a common cause? Inflammation, oxysterols, vasculature. BMC Geriatr. 2014, 14:36.
31. Leoni V., Caccia C. 24S-hydroxycholesterol in plasma: a marker of cholesterol turnover in neurodegenerative diseases. Biochimie 2013, 95:595-612.
32. Wood W.G., Li L., Muller W.E., Eckert G.P. Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis. J. Neurochem. 2014, 129:559-572.
33. Frieden C., Garai K. Structural differences between apoE3 and apoE4 may be useful in developing therapeutic agents for Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:8913-8918.
34. Barthel H., Gertz H.J., Dresel S., et al. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011, 10:424-435.
35. Zhu L., Zhong M., Elder G.A., et al. Phospholipid dysregulation contributes to ApoE4-associated cognitive deficits in Alzheimer's disease pathogenesis. Proc. Natl. Acad. Sci. U. S. A. 2015, 112:11965-11970.
36. Ye S., Huang Y., Mullendorff K., et al. Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:18700-18705.
37. Shibata N., Ohnuma T., Higashi S., et al. No genetic association between PCSK9 polymorphisms and Alzheimer's disease and plasma cholesterol level in Japanese patients. Psychiatr. Genet. 2005, 15:239.
38. Reynolds C.A., Hong M.G., Eriksson U.K., et al. Analysis of lipid pathway genes indicates association of sequence variation near SREBF1/TOM1L2/ATPAF2 with dementia risk. Hum. Mol. Genet. 2010, 19:2068-2078.
39. Kysenius K., Muggalla P., Matlik K., Arumae U., Huttunen H.J. PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling. Cell. Mol. Life Sci. 2012, 69:1903-1916.
40. Cully M. Dyslipidaemia: RNAi targeting PCSK9 decreases lipid levels in a human trial. Nat. Rev. Cardiol. 2013, 10:682.
41. Wu C.Y., Tang Z.H., Jiang L., Li X.F., Jiang Z.S., Liu L.S. PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway. Mol. Cell. Biochem. 2012, 359:347-358.
42. Tang Z., Jiang L., Peng J., et al. PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-kappaB activation in THP-1-derived macrophages. Int. J. Mol. Med. 2012, 30:931-938.
43. Jonas M.C., Costantini C., Puglielli L. PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1. EMBO Rep. 2008, 9:916-922.
44. Ko M.H., Puglielli L. Two endoplasmic reticulum (ER)/ER Golgi intermediate compartment-based lysine acetyltransferases post-translationally regulate BACE1 levels. J. Biol. Chem. 2009, 284:2482-2492.
45. Liu M., Wu G., Baysarowich J., et al. PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain. J. Lipid Res. 2010, 51:2611-2618.
46. Grosheva I., Haka A.S., Qin C., Pierini L.M., Maxfield F.R. Aggregated LDL in contact with macrophages induces local increases in free cholesterol levels that regulate local actin polymerization. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1615-1621.
47. Terrand J., Bruban V., Zhou L., et al. LRP1 controls intracellular cholesterol storage and fatty acid synthesis through modulation of Wnt signaling. J. Biol. Chem. 2009, 284:381-388.
48. Liu Q., Trotter J., Zhang J., et al. Neuronal LRP1 knockout in adult mice leads to impaired brain lipid metabolism and progressive, age-dependent synapse loss and neurodegeneration. J. Neurosci. 2010, 30:17068-17078.
49. Chen J.H., Hsieh C.J., Huang Y.L., et al. Genetic polymorphisms of lipid metabolism gene SAR1 homolog B and the risk of Alzheimer's disease and vascular dementia. J. Formos. Med. Assoc. 2015.
50. Liu Q., Zerbinatti C.V., Zhang J., et al. Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron 2007, 56:66-78.
51. Shi Y.M., Zhou H., Zhang Z.J., et al. Association of the LRP1 gene and cognitive performance with amnestic mild cognitive impairment in elderly Chinese. Int. Psychogeriatr. 2009, 21:1072-1080.
52. Vazquez-Higuera J.L., Mateo I., Sanchez-Juan P., et al. Genetic interaction between tau and the apolipoprotein E receptor LRP1 increases Alzheimer's disease risk. Dement. Geriatr. Cogn. Disord. 2009, 28:116-120.
53. Fuentealba R.A., Liu Q., Zhang J., et al. Low-density lipoprotein receptor-related protein 1 (LRP1) mediates neuronal Abeta42 uptake and lysosomal trafficking. PLoS One 2010, 5.
54. Zlokovic B.V. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat. Rev. Neurosci. 2011, 12:723-738.
55. Shibata M., Yamada S., Kumar S.R., et al. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 2000, 106:1489-1499.
56. Pflanzner T., Janko M.C., Andre-Dohmen B., et al. LRP1 mediates bidirectional transcytosis of amyloid-beta across the blood-brain barrier. Neurobiol. Aging 2011, 32. 2323.e2321-2311.
57. Sagare A., Deane R., Bell R.D., et al. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat. Med. 2007, 13:1029-1031.
58. Tamaki C., Ohtsuki S., Iwatsubo T., et al. Major involvement of low-density lipoprotein receptor-related protein 1 in the clearance of plasma free amyloid beta-peptide by the liver. Pharm. Res. 2006, 23:1407-1416.
59. Mackic J.B., Bading J., Ghiso J., et al. Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions. Vasc. Pharmacol. 2002, 38:303-313.